PVT1 and cancer: The results suggested that elevated PVT1 expression predicted a poor clinical outcome for OS in nine types of cancers (HR = 1.40, 95% CI: 1.21–1.59, P < 0.001) with no heterogeneity (I2 = 0.0%, P = 0.907).